Are biosimilars for Pemphigus safe

First line therapy for the autoimmune blistering disease (AIBD), pemphigus, has recently changed from high dose systemic corticosteroids to rituximab, a monoclonal antibody targeting CD-20 since the FDA registered rituximab (Mabthera US Licence 1048)1 . Although the efficacy and safety of rituximab has been established in pemphigus and other autoimmune conditions, less is known about the safety of biosimilars in pemphigus as they have been tested in rheumatoid arthritis. Biosimilars resemble the original biological drug, containing a version of the active component of an already approved product.